arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CapsoVision, Inc

CV
$6.20 ▼ -0.68 (-9.95%) at close
Healthcare ·Electromedical & Electrotherapeutic Apparatus ·USElectromedical & Electrotherapeutic Apparatus
11 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
10
Health
Poor
Bearish
auto_awesome

Analytical Summary

CapsoVision, Inc faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $309.6M
Dividend Yield —
Revenue Growth 9.9% ↗
Op. Margin -208.1% ↗
ROIC -57.6% ↘
FCF / Share $-0.17 ↘
Trailing P/E —
Price / Book 23.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

11-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.64M
↑ +9.9% —
Net Income Profit after all expenses
$-7.03M
↓ -30.8% —
Operating Margin Operating profit as % of sales
-208.1%
↑ +18.1% 0th
FCF / Share Free cash flow per share
$-0.17
↓ -30.6% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns
3
Financial Health
3
Cash Quality ↓
61

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 3 years · 11 quarters